DermTech, Inc. (DMTK)
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States.
It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions.
The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways.
In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies.
The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
|Industry||Diagnostics & Research|
|CEO||Dr. John D. Dobak M.D.|
11099 N. Torrey Pines Road, Suite 100
La Jolla, California 92037
|Fiscal Year||January - December|
|Dr. John D. Dobak M.D.||President, Chief Executive Officer and Director|
|Kevin Sun M.B.A.||Chief Financial Officer, Treasurer and Secretary|
|Claudia Ibarra||Chief Operating Officer|
|Ray Akhavan J.D.||General Counsel|
|Todd Michael Wood||Chief Commercial Officer|
|William W. Zondler||Chief Information Officer|
|Steve E. Kunszabo||Senior Director of Investor Relations|
|Jennifer Eilemberg||Chief Compliance Officer|
|Ray Bassi||Vice President of Sales|
|Dr. Burkhard Jansen M.D.||Chief Medical Affairs Officer|
Latest SEC Filings
|Mar 13, 2023||8-K||Current Report|
|Mar 3, 2023||S-8||Securities to be offered to employees in employee benefit plans|
|Mar 2, 2023||10-K||Annual Report|
|Mar 2, 2023||8-K||Current Report|
|Feb 14, 2023||SC 13G/A||[Amend] Statement of acquisition of beneficial ownership by individuals|
|Feb 3, 2023||SC 13G/A||[Amend] Statement of acquisition of beneficial ownership by individuals|
|Nov 15, 2022||8-K/A||[Amend] Current report|
|Nov 14, 2022||8-K||Current Report|
|Nov 8, 2022||SC 13D/A||[Amend] General statement of acquisition of beneficial ownership|
|Nov 3, 2022||10-Q||Quarterly Report|